Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jonathan Demchick maintains an Equal-Weight rating on NuVasive (NASDAQ:NUVA) and lowers the price target from $43 to $40.
May 31, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Equal-Weight rating on NuVasive and lowers the price target from $43 to $40.
The news directly mentions NuVasive and its lowered price target by Morgan Stanley. The Equal-Weight rating suggests that the stock is expected to perform in line with the market, and the lowered price target may have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100